Tonix Pharmaceuticals Holding (TNXP) Receivables (2023 - 2026)

Tonix Pharmaceuticals Holding's Receivables history runs 4 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• On a quarterly basis, Receivables rose 165.38% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $12.2 million, a 165.38% increase from a year earlier, with the FY2025 full-year figure at $9.8 million, up 110.44% from the prior year.
• Receivables grew to $12.2 million in Q1 2026 per TNXP's latest filing, from $9.8 million in the prior quarter.
• Across five years, Receivables topped out at $12.2 million in Q1 2026 and bottomed at $1.6 million in Q3 2023.
• The 4-year median for Receivables is $4.6 million (2024), against an average of $5.8 million.
• Across the five-year window, Receivables plunged 49.5% in 2024 and jumped 165.38% in 2026, its largest moves.
• Year by year, Receivables stood at $9.2 million in 2023, then sank by 49.5% to $4.6 million in 2024, then soared by 110.44% to $9.8 million in 2025, then increased by 25.15% to $12.2 million in 2026.
• Per Business Quant, the three latest TNXP Receivables figures stand at $12.2 million (Q1 2026), $9.8 million (Q4 2025), and $5.1 million (Q3 2025).